PBS updates

Onureg (Azacitidine)

azacitidine 300 mg tablet, 7 · ORAL · PBS code 13619T

AUTHORITY_REQUIRED

What it costs

AU$6613.88 PBS-determined price per 14 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2023-09-01.
  • • Repeats: 2.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Acute Myeloid Leukaemia


Treatment following intensive induction chemotherapy - Initial treatment


Patient must have demonstrated either: (i) first complete remission, (ii) complete remission with incomplete blood count recovery following intensive induction chemotherapy; AND

Patient must not be a candidate for, including those who choose not to proceed to, haematopoietic stem cell transplantation; AND

Patient must have, at the time of induction therapy, a cytogenetic risk classified as either: (i) intermediate-risk, (ii) poor-risk; AND

Patient must not have undergone a stem cell transplant; AND

Patient must not be receiving concomitant PBS-subsidised treatment with midostaurin.

A complete remission is defined as: bone marrow blasts of less than 5%, absence of blasts with Auer rods, absence of extramedullary disease, independent of blood transfusions and a recovery of peripheral blood counts with peripheral neutrophil count greater than 1.0 x 109/L and platelet count greater than or equal to 100 x 109/L.

A complete remission with incomplete blood count recovery is defined as bone marrow blasts of less than 5%, absence of blasts with Auer rods, absence of extramedullary disease, independent of blood transfusions and a recovery of peripheral blood counts with peripheral neutrophil count less than 1.0 x 109/L or platelet count less than 100 x 109/L.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Acute Myeloid Leukaemia


Treatment following intensive induction chemotherapy - Continuing treatment


Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must have, for reasons not attributable to any cause other than AML, no more than 15% blasts in either the: (i) bone marrow, (ii) peripheral blood; AND

Patient must not be receiving concomitant PBS-subsidised treatment with midostaurin.

Sponsor: Bristol-Myers Squibb Australia Pty Ltd ABN 33 004 333 322

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.